La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Greenwich LifeSciences Gestione
Gestione criteri di controllo 1/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Snehal Patel
Amministratore delegato
US$2.8m
Compenso totale
Percentuale dello stipendio del CEO | 20.2% |
Mandato del CEO | 14.5yrs |
Proprietà del CEO | 42.1% |
Durata media del management | Nessun dato |
Durata media del Consiglio di amministrazione | 14.5yrs |
Aggiornamenti recenti sulla gestione
Recent updates
We Think Greenwich LifeSciences (NASDAQ:GLSI) Can Afford To Drive Business Growth
Aug 22Greenwich LifeSciences: Trying To Move A Needle That Doesn't Like To Budge
Jun 26Here's Why We're Not Too Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Situation
Jan 12We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate
Jan 29Greenwich LifeSciences: Persevering CEO And Interesting Data
Sep 06Greenwich LifeSciences halts stock buyback program
Jul 11Greenwich LifeSciences: A First Look
May 19Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential
Apr 21Companies Like Greenwich LifeSciences (NASDAQ:GLSI) Are In A Position To Invest In Growth
Feb 01We Think Greenwich LifeSciences (NASDAQ:GLSI) Can Afford To Drive Business Growth
Sep 30We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate
Apr 04Are Insiders Buying Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock?
Feb 16What Is The Ownership Structure Like For Greenwich LifeSciences, Inc. (NASDAQ:GLSI)?
Dec 25Greenwich LifeSciences: Optimism On 'GP2' Breast Cancer Immunotherapy Candidate
Dec 23Greenwich LifeSciences under stress on pricing upsized $26.4M equity offering
Dec 18Greenwich LifeSciences inks deal with Westport Bio for pre-clinical coronavirus vaccine candidates
Dec 15Greenwich LifeSciences trebles in value as breast cancer therapy shines in mid-stage trial
Dec 09Analisi delle retribuzioni degli amministratori delegati
Data | Compenso totale | Stipendio | Guadagni aziendali |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$10m |
Mar 31 2024 | n/a | n/a | -US$9m |
Dec 31 2023 | US$3m | US$557k | -US$9m |
Sep 30 2023 | n/a | n/a | -US$9m |
Jun 30 2023 | n/a | n/a | -US$9m |
Mar 31 2023 | n/a | n/a | -US$8m |
Dec 31 2022 | US$2m | US$506k | -US$8m |
Sep 30 2022 | n/a | n/a | -US$7m |
Jun 30 2022 | n/a | n/a | -US$6m |
Mar 31 2022 | n/a | n/a | -US$6m |
Dec 31 2021 | US$1m | US$450k | -US$5m |
Sep 30 2021 | n/a | n/a | -US$3m |
Jun 30 2021 | n/a | n/a | -US$3m |
Mar 31 2021 | n/a | n/a | -US$2m |
Dec 31 2020 | US$999k | US$115k | -US$2m |
Sep 30 2020 | n/a | n/a | -US$1m |
Jun 30 2020 | n/a | n/a | -US$1m |
Mar 31 2020 | n/a | n/a | -US$4m |
Dec 31 2019 | US$139k | n/a | -US$3m |
Compensazione vs Mercato: La retribuzione totale di Snehal ($USD 2.75M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 1.54M ).
Compensazione vs guadagni: La retribuzione di Snehal è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Snehal Patel (60 yo)
14.5yrs
Mandato
US$2,750,029
Compensazione
Mr. Snehal S. Patel has been Chief Executive Officer of Greenwich Lifesciences Inc. since June 2016 and has been Chief Financial Officer and Director since February 2010. He serves as Managing Director at...
Membri del Consiglio di amministrazione
Nome | Posizione | Mandato | Compensazione | Proprietà |
---|---|---|---|---|
CEO, CFO & Director | 14.5yrs | US$2.75m | 42.11% $ 81.9m | |
Founder & Independent Director | 18yrs | US$65.64k | 2.38% $ 4.6m | |
Chief Medical Officer & Director | 4.9yrs | Nessun dato | 0.69% $ 1.3m | |
Independent Chairman of the Board | 15.5yrs | US$98.39k | 4.72% $ 9.2m | |
Independent Director | 4.9yrs | US$65.64k | 3.02% $ 5.9m |
14.5yrs
Durata media
73yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di GLSI è composto da personale esperto e esperto (durata media dell'incarico 14.5 anni).